HEALTHCARE RESOURCE UTILISATION IN ADVANCED MELANOMA- AN ANALYSIS FROM THE MELODY OBSERVATIONAL STUDY

Author(s)

Lorigan P1, Maio M2, Middleton M3, Testori A4, Bédane C5, van Baardewijk M6, Konto C7, Dueymes A8, Lebbe C91The Christie NHS Foundation Trust,, Manchester, Cheshire, United Kingdom, 2University Hospital of Siena, Siena, Italy, 3Churchill Hospital, Oxford, United Kingdom, 4Istituto Europeo di Oncologia, Milan, Italy, 5Hopital Dupuytren, Limoges , France, 6Bristol-Myers Squibb, Brussels, Belgium, 7Bristol-Myers Squibb, Paris , France, 8PAREXEL International, Semoy, France, 9Hopital Saint Louis, Paris, France

OBJECTIVES: We conducted this study to document the health care resource utilisation associated with treatment of patients with advanced melanoma. METHODS: MELODY (Melanoma treatment patterns and outcomes among patients with unresectable stage III or stage IV disease: a retrospective longitudinal survey) is an observational study managed at 31 centres in France, Italy and the UK. Eligible patients had attended at one of the sites with a diagnosis of unresectable Stage III or IV melanoma between July 1, 2005 and June 30, 2006; data were retrieved from diagnosis (no limit date) until 2008. The primary objective was to document the first-line treatments received by patients. Secondary objectives included ascertaining healthcare resource utilisation related to up to 3 lines of treatment (anticancer and supportive care). Data were collected from patients (n=776) using a case-report form that included information on hospitalisations, outpatient visits, hospice care and adverse-event management (transfusions and concomitant medications including antiemetics and growth factors). Resource use data were collected from patients (n=606) that received systemic treatment outside a clinical trial and/or supportive care. RESULTS: Twenty-nine percent (176/606) of patients required medical management for treatment-related adverse events and 32% (195/606) were hospitalised while receiving systemic treatment and/or supportive care with 25% of these having at least 4 hospitalisations. The median duration of hospitalisation was 17 days, with 25% spending at least 29 days in hospital (may comprise multiple stays). The hospitalisation rate was higher in patients receiving supportive care than those receiving anticancer treatment (86/170; 51% vs. 140/553; 25%), but median duration of hospitalisation was similar (15.0 vs. 14.5 days). Results by line of anticancer therapy and supportive care will be presented. CONCLUSIONS: These results from MELODY suggest that the systemic and palliative treatments used to manage advanced melanoma are associated with considerable resource utilisation, highlighting the need for more effective treatment options.

Conference/Value in Health Info

2010-11, ISPOR Europe 2010, Prague, Czech Republic

Value in Health, Vol. 13, No. 7 (November 2010)

Code

PCN111

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×